DDInter1851 DDInter915
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Trazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Trazodone {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Trazodone {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) interacts with {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Trazodone {u} (Compound) resembles {v} (Compound) Aripiprazole
Aripiprazole {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Trazodone {u} may lead to a major life threatening interaction when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Trazodone {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Trazodone (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Indacaterol (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Trazodone (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) interacts with ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Trazodone (Compound) resembles Aripiprazole (Compound) and Aripiprazole (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Trazodone may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Trazodone (Compound) resembles Loxapine (Compound) and Loxapine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)